Related Experiment Video
Updated: Jun 5, 2026
06:07
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
Published on: October 22, 2020
Waterpipe Smoking And The DRD2/ANKK1 Genotype
Ghada N Radwan1, Christopher A Loffredo, Maged A El Setouhy
1Dept. of Public Health, Cairo University, Cairo, Egypt. gnasr@theunion.org.
The Journal of the Egyptian Public Health Association
|January 20, 2011
Summary
Waterpipe smoking addiction may be linked to DRD2 gene variations. The A1 genotype was associated with shorter craving duration and frequent cafe visits among waterpipe smokers.
Area of Science:
- Genetics
- Epidemiology
- Addiction Research
Background:
- Waterpipe smoking is a growing global health concern.
- Limited research exists on the genetic factors influencing waterpipe smoking behavior and addiction.
- The DRD2 gene polymorphism (TaqI) has been previously associated with cigarette smoking due to its role in the dopamine reward system.
Purpose of the Study:
- To investigate the association between DRD2 gene variations and waterpipe smoking behavior, addiction, and motives in Egyptian rural males.
- To explore potential genetic determinants of waterpipe smoking addiction.
Main Methods:
- A case-control study involving 154 adult male waterpipe smokers (non-cigarette smokers) from a rural Egyptian survey.
- Participants were interviewed regarding smoking habits and motives.
- Genotyping for DRD2 gene polymorphism (A1 vs. A2 alleles) was performed using PCR.
Main Results:
- The A1 genotype (34.4% prevalence) was significantly associated with a shorter duration to craving after abstinence (OR 2.70, 95% CI: 1.18-6.23).
- A1 allele carriers were more likely to be frequent visitors of shisha cafes, younger, and heavier smokers (OR 2.52, 95% CI: 1.06-6.02).
Conclusions:
- Inherited variations in the DRD2 genotype may influence the intensity of waterpipe smoking craving.
- Frequency of visiting shisha cafes for smoking might be linked to DRD2 gene variations.
Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...